Table 3. Outcomes in patients with unresectable HCC treated with TACE group and non-TACE group.
| Variable | RECIST 1.1 | mRECIST | |||||
|---|---|---|---|---|---|---|---|
| TACE group (n=98) | Non-TACE group (n=49) | P value | TACE group (n=98) | Non-TACE group (n=49) | P value | ||
| Best overall response, n (%) | – | – | |||||
| CR | 0 (0.0) | 0 (0.0) | 22 (22.4) | 4 (8.2) | |||
| PR | 38 (38.8) | 13 (26.5) | 51 (52.0) | 16 (32.7) | |||
| SD | 51 (52.0) | 21 (42.9) | 16 (16.3) | 16 (32.7) | |||
| PD | 9 (9.2) | 15 (30.6) | 9 (9.2) | 13 (26.5) | |||
| ORR (CR + PR) | 38 (38.8) | 13 (26.5) | 0.141 | 73 (74.4) | 20 (40.8) | <0.001 | |
| DCR (CR + PR + SD) | 89 (90.8) | 34 (69.4) | 0.001 | 89 (90.8) | 36 (73.5) | 0.005 | |
Outcomes were determined according to the Response Evaluation Criteria in Solid Tumors, version 1.1 and modified Response Evaluation Criteria in Solid Tumors. Non-TACE group refers to patients who received systemic combination therapy without TACE. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate.